FDA warns compounding pharmacy over mass production of GLP-1 drug copies

The U.S. Food and Drug Administration has issued a warning to a major compounding pharmacy, alleging it violated federal law by producing copies of blockbuster weight-loss drugs in inordinate amounts. The agency's intervention targets the large-scale replication of these therapies, which are typically prescribed for obesity and diabetes management. This enforcement action highlights regulatory scrutiny on the supply chain for popular GLP-1 medications, where compounding pharmacies have increasingly offered lower-cost alternatives to branded versions. The FDA's citation specifically cites the volume of production as the core legal violation, distinguishing standard patient-specific compounding from mass manufacturing practices.